Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDACNBC • 12/07/19
Questions Linger After CTAD For Biogen's Aducanumab, But Trading Opportunities ExistSeeking Alpha • 12/06/19
Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's?Investors Business Daily • 12/06/19
Biogen Stock Popped: Here's What Happened In Its Alzheimer's UpdateInvestors Business Daily • 12/05/19
Biogen Inc. (BIIB) Management Presents at Evercore ISI 2nd Annual HealthCONx Conference (Transcript)Seeking Alpha • 12/04/19
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)GlobeNewsWire • 12/03/19
Biogen's stock could fall 10% on new Alzheimer's drug data this week, top analyst saysCNBC • 12/02/19
Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In DowngradeBenzinga • 12/02/19
Biogen Stock Is Facing A Crucial Test — Here's What You Need To KnowInvestors Business Daily • 12/02/19